王佳蕊,冯江龙,杨文秀
WANG Jiarui,FENG Jianglong,YANG Wenxiu

• 1:贵州医科大学病理学教研室

摘要(Abstract)：

目的:用聚丙烯酸甲酯/离子霉素(PMA/IONO)和MALT1抑制剂Z-VRPR-FMK刺激Burkitt淋巴瘤细胞,检测细胞内MALT1和A20蛋白的表达。方法:采用200μg/L+1μmol/L的PMA/IONO和不同浓度(25、50和75μmol/L)的Z-VRPR-FMK、在不同的作用时间(0.25、0.5和2 h)下刺激培养的Burkitt淋巴瘤细胞Raji,根据各组细胞中A20蛋白的表达情况确定抑制剂Z-VRPR-FMK的最佳作用浓度及时间;将培养的Raji细胞分为设对照组、激动剂PMA/IONO处理组和抑制剂Z-VRPR-FMK处理组;对照组不加入Z-VRPR-FMK和PMA/IONO处理,抑制剂Z-VRPR-FMK处理组和激动剂PMA/IONO处理组分别根据筛选的Z-VRPR-FMK最佳作用浓度和时间进行刺激培养,采用Western bloting法各组检测各组细胞中MALT1和A20蛋白的表达。结果:最适的ZVRPR-FMK作用浓度为75μmol/L、作用时间为0.5 h;与对照组相比,激动剂PMA/IONO处理组与抑制剂Z-VRPR-FMK处理组MALT1蛋白表达差异无统计学意义(P>0.05),但两组的A20蛋白表达均明显升高(P<0.01)。结论:抑制剂Z-VRPR-FMK能促进培养的Raji细胞内A20蛋白表达上调。
Objective: To stimulate cultured Burkitt lymphoma cell with PMA/IONO and Z-VRPRFMK separately,and detect the expression of MALT1 and A20 protein. Methods: Raji cells were cultured. According to A20 protein expression condition,the best concentration and time of Z-VRPRFMK was screened by using different concentration( 25 μmol/L,50 μmol/L,75 μmol/L) and time( 0. 25 h,0. 5 h,2 h) of Z-VRPR-FMK as well as 200 mg/L and 1 μmol/L PMA/IONO. Cultured Raji cells were divided into control group and PMA/IONO agonist treatment group and inhibitor Z-VRPR-FMK treatment group,control group didn't treat with Z-VRPR-FMK or PMA/IONO,PMA/IONO agonist treatment group and inhibitor Z-VRPR-FMK treatment group were given Z-VRPR-FMK at screened optimum concentration and time. MALT1 and A20 protein was detected by western blotting.Results: The best concentration and time of Z-VRPR-FMK were 75 μmol/L and 0. 5 h separately.Compared with control,there was no change of MALT1 expression in two experimental groups,but A20 expression was significantly increased in the two groups( P < 0. 01). Conclusion: The inhibitor Z-VRPR-FMK can promote the expression of A20 protein in cultured Raji cells.

关键词(KeyWords)： 淋巴瘤;细胞蛋白;MALT1;Z-VRPR-FMK
lymphoma;cell protein;MALT1;Z-VRPR-FMK

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81160299)

作者(Author): 王佳蕊,冯江龙,杨文秀
WANG Jiarui,FENG Jianglong,YANG Wenxiu

DOI: 10.19367/j.cnki.1000-2707.2017.10.003

参考文献(References)：

• [1]Francesco T.Constitutive NF-κB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma[J].Biomed Research International,2015(23):1-5.
• [2]Espinosa I,Briones J,Bordes R,et al.Activation of the NFkappa B signalling pathway in diffuse large B-cell lymphoma:clinical implications[J].Histopathology,2008(4):441-449.
• [3]Staudt LM.Oncogenic activation of NF-kappa B[J].Cold Spring Harb Perspect Biol,2010(6):1-30.
• [4]Chanudet E,Huang Y,Ichimura K,et al.A20 is targeted by promoter methylation deletion and inactivating mutation in MALT lymphoma[J].Leukemia,2010(2):483-487.
• [5]Yugo M,Kaoru A,Shuhei T,et al.MUC1 protein induces urokinase-type plasminogen activator(u PA)by forming a complex with NF-κB p65 transcription factor and binding to the u PA promoter,leading to enhanced invasiveness of cancer cells[J].The Journal of Biological Chemistry,2014(289):35193-35204.
• [6]Turturro F.Constitutive NF-κB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma[J].Biomed Res Int.2015,2015:54-62.
• [7]Grégoire M,Guilloton F.Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas[J].Oncotarget,2015(18):16471-16487.
• [8]Karim ZA,Vemana HP,Khasawneh FT.MALT1-ubiquitination triggers non-genomic NF-κB/IKK signaling upon platelet activation[J].Plos One,2015(3):672-678.
• [9]Mcallisterlucas LM,Baens M,Lucas PC.MALT1 protease:a new therapeutic target in B lymphoma and beyond?[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research,2011(21):6623-6631.
• [10]Karim ZA,Vemana HP,Khasawneh FT.MALT1-ubiquitination triggers non-genomic NF-κB/IKK signaling upon platelet activation[J].Plos One,2015(3):215-219.
• [11]Linda M,Mc Allister-Lucas,Mathijs B,et al.MALT1Protease:A new therapeutic target in B lymphoma and beyond[J].Clin Cancer Res,2011(21):6623-6631.

文章评论(Comment)：